AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35752091
Drug: 8 mg/ml
RxNorm normalized name: valine 8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/ml e‐cigarette
Trial: 35752091
Drug: 0 mg/ml
RxNorm normalized name: urea 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/ml e‐cigarette
Trial: 36228453
Drug: ISP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISP group received bilateral ultrasound guided ISP block at the level of C5 using 20 ml bupivacaine 0.25% on each side
Trial: 34910161
Drug: HIIT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIIT with FOS-enriched inulin (12 g·d‐1)
Trial: 33784438
Drug: Antenatal nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal nutritional supplements
Trial: 34371872
Drug: Peptide formula
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide formula (PF) 1.5 kcal/mL
Trial: 34403141
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of intravenous squalene twice a day and standard treatment for 6 days
Trial: 35488787
Drug: Esketamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (0.3 mg/kg) combined with propofol
Trial: 35488787
Drug: Dezocine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine (0.05 mg/kg) combined with propofol
Trial: 32621262
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) associated with Preventive Oral Care Program (POCP)
Trial: 33534895
Drug: Nolasiban 900
RxNorm normalized name: Nolasiban
DrugBank: Nolasiban (DB16259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nolasiban 900 mg
Trial: 33739022
Drug: Nolasiban 1800
RxNorm normalized name: Nolasiban
DrugBank: Nolasiban (DB16259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nolasiban 1800 mg
Trial: 33739022
Drug: Sex hormones
RxNorm normalized name: GENITO URINARY SYSTEM AND SEX HORMONES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormones (independent assessment)
Trial: 32020824
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (0.04% tretinoin microspheres + 1% clindamycin)
Trial: 32020824
Drug: Monotherapy (0.025%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (0.025% tretinoin)
Trial: 32020824
Drug: Monotherapy (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (1% clindamycin)
Trial: 32082606
Drug: Oral probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotics
Trial: 35041627
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen plus 500 mL PEG after SBCE ingestion (prep 2)
Trial: 35041627
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen plus 2 L PEG plus 500 mL PEG after SBCE ingestion (prep 3)
Trial: 33373286
Drug: Spray-inoculated with
RxNorm normalized name: dimethicone / zinc oxide Topical Spray [Rash Relief with Zinc Oxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray-inoculated with a suspension of conidia (1×10^5 spores/ml) for 7 days
Trial: 36152778
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol (target level: 0.05 g%)
Trial: 33383230
Drug: Mind (tablet‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mind (tablet‐based cognitive training)
Trial: 34348526
Drug: Drospirenone 4
RxNorm normalized name: drospirenone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 4 mg
Trial: 32664877
Drug: Cinepazide maleate
RxNorm normalized name: cinepazide maleate
DrugBank: Cinepazide (DB12123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinepazide maleate injection (320 mg, intravenous infusion, once daily for 14 days)
Trial: 33468249
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate (GS; 1500 mg) and bovine chondroitin sulfate (CS; 1200 mg)
Trial: 34889733
Drug: Topiroxostat 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 200 mg
Trial: 34889733
Drug: Topiroxostat 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 80 mg
Trial: 34889733
Drug: Allopurinol 200
RxNorm normalized name: allopurinol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 200 mg
Trial: 34889733
Drug: Topiroxostat 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 120 mg
Trial: 34889733
Drug: Topiroxostat 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 160 mg
Trial: 34889733
Drug: Topiroxostat 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 40 mg
Trial: 34397820
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration simethicone solution (S2‐)
Trial: 34397820
Drug: Low concentration
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concentration simethicone solution (S1‐)
Trial: 32941395
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) Cmin of 4-7 ng/mL
Trial: 32941395
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) Cmin of 4-7 ng/mL after propensity score matching
Trial: 32941395
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) Cmin of 7-10 ng/mL
Trial: 32941395
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) Cmin of >10 ng/mL
Trial: 34191033
Drug: NAD+-precursor supplementation
RxNorm normalized name: nicotinamide adenine dinucleotide (NAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAD+-precursor supplementation (207.5 mg niacin equivalents/day) for 32 days
Trial: 32435772
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with chitosan nanoparticles (Csnp) solution under ultrasonic agitation for 60 s and immersed in EDC crosslinker for 24 h
Trial: 32522244
Drug: Cefixime 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 400 mg orally two times per day for 10 days (n = 140)
Trial: 32522244
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin G 2.4 million units intramuscularly based on the stage of syphilis infection (n = 70)
Trial: 32977975
Drug: As-needed acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed acetaminophen + codeine
Trial: 32977975
Drug: Scheduled acetaminophen/as-needed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled acetaminophen/as-needed tramadol
Trial: 35784564
Drug: MMI monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMI monotherapy
Trial: 32827483
Drug: Intravenous cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisplatin
Trial: 35123569
Drug: Internet-supported mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-supported mindfulness-based cognitive therapy (MBCT) for 8 weeks with weekly group sessions via videoconference, asynchronous homework, an online retreat after the fifth week, and 4 monthly booster sessions after completion of the 8-week programme.
Trial: 37038176
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control treatment
Trial: 35868146
Drug: Once-weekly LAGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly LAGH (0.7 mg/kg/week)
Trial: 35868146
Drug: Daily GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily GH (0.37 mg/kg/week)
Trial: 32645310
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of mitomycin C (MMC)
Trial: 34462956
Drug: Synbiotic capsules
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic capsules
Trial: 33108247
Drug: MARS compared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MARS compared with caregiver-reported medication adherence
Trial: 33108247
Drug: MARS compared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MARS compared with Asthma Medication Ratio (AMR), asthma control, and caregiver perception of asthma control
Trial: 35320964
Drug: Intrathecal 3
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal 3 mg hyperbaric bupivacaine 0.5% plus 20 microgram fentanyl and intravenous fentanyl at 1μg.kg(‐1).h(‐1)
Trial: 35320964
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl at 1μg.kg(‐1).h(‐1) and laparoscopic port site infiltration with 0.5% bupivacaine
Trial: 35929466
Drug: Fluoxetine intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine intervention
Trial: 35929466
Drug: No fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No fluoxetine intervention (Control)
Trial: 36380693
Drug: Tofacitinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (10 mg/bid for 2 weeks)
Trial: 32485656
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg MAS-ER
Trial: 32485656
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg MAS-ER
Trial: 32208351
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (3 cycles of epirubicin, cisplatin or oxaliplatin and capecitabine) followed by surgery and either postoperative chemotherapy or chemoradiotherapy (45Gy + cisplatin + capecitabine)
Trial: 34480630
Drug: Cannabidiol 600
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol 600 mg
Trial: 35447145
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% imiquimod cream
Trial: 35357290
Drug: Carbon ion
RxNorm normalized name: CARBON ION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon ion therapy
Trial: 33664007
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg per day)
Trial: 35905339
Drug: Previous L‐independent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous L‐independent approaches (e.g., qDRIFT)
Trial: 32666349
Drug: Probiotic gel
RxNorm normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic gel and lozenges (n=20)
Trial: 36191882
Drug: Adebrelimab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab (20 mg/kg on day 1), nab-paclitaxel (100 mg/m2 on days 1, 8, and 15), and carboplatin (AUC 5 mg/mL per min on day 1) as neoadjuvant treatment followed by 16 cycles of adebrelimab (20 mg/kg on day 1 every 3 weeks) as adjuvant treatment.
Trial: 33951024
Drug: Indwelling analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indwelling analgesic catheter (IC)
Trial: 33951024
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose liposomal bupivacaine (LB)
Trial: 32648394
Drug: Waiting-list group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list group (no intervention except ibuprofen when necessary).
Trial: 39047240
Drug: Chemotherapy-only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-only
Trial: 35301859
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg glibenclamide
Trial: 32251303
Drug: Dietary restriction
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary restriction (DR) - formula diet containing 60% of daily energy requirement during the 4-day interval before PCI
Trial: 32251303
Drug: Dietary restriction
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary restriction (DR) - formula diet containing 60% of daily energy requirement
Trial: 34511586
Drug: IV OPC‐61815
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV OPC‐61815 16 mg
Trial: 34511586
Drug: Oral tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tolvaptan 15 mg
Trial: 32001003
Drug: Naturalistic controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naturalistic controls (treatment as usual)
Trial: 33449534
Drug: Amantadine sulfate
RxNorm normalized name: amantadine sulfate
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine sulfate (400 mg/day intravenously for 4 days, followed by oral administration at 400 mg/day for 6 days)
Trial: 33449534
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy according to the order of the Ministry of Health of the Russian Federation No. 928n
Trial: 34967830
Drug: Sham control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control (riboflavin ophthalmic solution)
Trial: 32369007
Drug: Computerised speech
RxNorm normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerised speech and language therapy
Trial: 34399136
Drug: Video directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video directly observed therapy (DOT) using a HIPAA-compliant smartphone application
Trial: 33528004
Drug: Tailored Therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored Therapeutic Exercise and Recovery Strategies (ATOPE) program, performed before treatment, with 12 to 18 sessions of tailored, high‐intensity exercise and post‐exercise recovery strategies.
Trial: 33612068
Drug: PSA-test; if
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA-test; if PSA ≥ 3 ng/mL, then MRI and systematic biopsy, plus targeted biopsy to suspicious lesions as per PI-RADSv2 3–5
Trial: 33612068
Drug: PSA-test; if
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA-test; if PSA ≥ 3 ng/mL, then MRI, and targeted biopsy only if PI-RADSv2 3–5
Trial: 33612068
Drug: Identical to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical to Arm 2, except lower PSA-cut-off ≥1.8 ng/mL
Trial: 32307933
Drug: LIPUS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIPUS therapy combined with Twin-Block appliance
Trial: 32307933
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (observational, no treatment)
Trial: 34028967
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg daily plus 177Lu-PSMA-617 7.5 GBq on Days 15 and 57 (up to four doses total)
Trial: 34028967
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg daily alone
Trial: 32618249
Drug: SoC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoC plus focal mass drug administration (fMDA)
Trial: 32618249
Drug: SoC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoC plus mass drug administration (MDA)
Trial: 32315461
Drug: Pharmacist-conducted medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-conducted medication review
Trial: 35545875
Drug: Topical product
RxNorm normalized name: Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical product (Group C) - cream formulation containing hydroxypinacolone/retinyl palmitate, Iris Florentina root extract, and a complex of three oligopeptides applied twice a day.
Trial: 35545875
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Group C + O) - topical product plus prebiotic food supplement (FOS&GOS, zinc, lactoferrin, niacinamide).
Trial: 34692934
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy group (CT) with conventional rehabilitation for 6 weeks
Trial: 33332873
Drug: Open biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open biological mesh
Trial: 33332873
Drug: Laparoscopic biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic biological mesh
Trial: 33332873
Drug: Biological mesh
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological mesh (overall)
Trial: 35531961
Drug: Newborn Behavioral
RxNorm normalized name: Vital E- Newborn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newborn Behavioral Observations (NBO) plus treatment as usual (TAU)
Trial: 35421875
Drug: Regular western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular western medicine (Control)
Trial: 616122612
Drug: Melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3 mg t.i.d for 1 month
Trial: 35882451
Drug: Education on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education on exercise and COVID‐19 recovery trajectory, physical activity and vitals monitoring, and weekly check‐ins with study staff (n=15)
Trial: 35320216
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality exercises with routine physical therapy
Trial: 36344629
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of mirabegron and solifenacin
Trial: 36344629
Drug: Solifenacin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin therapy (Control)
Trial: 35849476
Drug: relugolix-combination therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: relugolix-combination therapy (relugolix-CT)
Trial: 33038408
Drug: Autonomic regulation
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomic regulation therapy (ART) utilizing cervical vagus nerve stimulation (VNS) for 6 months post-titration
Trial: 36934987
Drug: Autonomic regulation
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomic regulation therapy (ART) utilizing cervical vagus nerve stimulation (VNS)
Trial: 32990858
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (placebo) injections
Trial: 33795299
Drug: Biological mesh
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological mesh repair
Trial: 33210178
Drug: Apremilast (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast (in vivo administration)
Trial: 33210178
Drug: PsO-MSCs T0
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PsO-MSCs T0 (before treatment)
Trial: 33210178
Drug: PsO-MSCs T12
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PsO-MSCs T12 (after treatment)
Trial: 33686446
Drug: Fractional laser-assisted
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional laser-assisted topical corticosteroid delivery
Trial: 33686446
Drug: Fractional laser
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional laser monotherapy
Trial: 33691056
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% (1 mL)
Trial: 33691056
Drug: Granisetron (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (1 mg in 1 mL)
Trial: 32306525
Drug: HSF™-based skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSF™-based skin care formulation